PDCD1 and hypoparathyroidism-retardation-dysmorphism syndrome: This paradoxical observation may explain the poor clinical response and unfavorable prognosis seen in some HRD patients who received anti‐PDCD1 monotherapy or PARPi plus anti‐PDCD1 combination therapy.